SCHEMBL3983281

SCHEMBL3983281

CC(=O)Nc1ccc(CC(=O)Nc2c(N)[nH]c(=O)n(Cc3ccccc3)c2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.46
PKM P14618 1/20 0.45
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 3/20 0.43
HTT P42858 1/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
USP1 O94782 1/20 0.42
PARP1 P09874 1/20 0.42
HPGD P15428 3/20 0.42
GAA P10253 2/20 0.42
EPHX2 P34913 1/20 0.42
PTPN1 P18031 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 1/20 0.41
MMP13 P45452 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3979338 0.88 PCK1 (0.47) NLRP3HTTPARP1GAAKDM4E
SCHEMBL8392000 0.79 ALDH1A1 (0.45) PKMRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL3981788 0.79 PKM (0.47) NLRP3PKMRAB9ASMN1; SMN2NPC1
SCHEMBL3979162 0.77 PKM (0.48) NLRP3PKMRAB9ASMN1; SMN2NPC1
SCHEMBL4614353 0.76 GLS (0.43) KDM4EMEN1KMT2AMAPT
SCHEMBL3976855 0.72 GAA (0.53) NLRP3PKMPARP1GAAALDH1A1
SCHEMBL25669896 0.71 EPHX2 (0.67) NLRP3RAB9ASMN1; SMN2NPC1BCHE
SCHEMBL7434388 0.71 KDM4E (0.67) SMN1; SMN2HPGDGAAALDH1A1KDM4E
SCHEMBL6385949 0.69 ADORA1 (0.47) NLRP3RAB9ASMN1; SMN2NPC1PARP1
SCHEMBL14267083 0.69 LMNA (0.41) SMN1; SMN2HTTHPGDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1515972-B1 AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY HOFFMANN LA ROCHE (CH) 2009-05-13 EP disclosed
US-7135475-B2 Antidiabetic agents HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
US-20040014766-A1 Amide substituted xanthine derivatives HOFFMANN-LA ROCHE INC. 2004-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014766-A1 Amide substituted xanthine derivatives GYS2, GLS2, PYGL NLRP3 2706/4885PKM 209/4885RAB9A 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.